102 related articles for article (PubMed ID: 21831962)
1. CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
Mine N; Yamamoto S; Saito N; Yamazaki S; Suda C; Ishigaki M; Kufe DW; Von Hoff DD; Kawabe T
Mol Cancer Ther; 2011 Oct; 10(10):1929-38. PubMed ID: 21831962
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
Sha SK; Sato T; Kobayashi H; Ishigaki M; Yamamoto S; Sato H; Takada A; Nakajyo S; Mochizuki Y; Friedman JM; Cheng FC; Okura T; Kimura R; Kufe DW; Vonhoff DD; Kawabe T
Mol Cancer Ther; 2007 Jan; 6(1):147-53. PubMed ID: 17237275
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
[TBL] [Abstract][Full Text] [Related]
4. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Shapiro GI; Tibes R; Gordon MS; Wong BY; Eder JP; Borad MJ; Mendelson DS; Vogelzang NJ; Bastos BR; Weiss GJ; Fernandez C; Sutherland W; Sato H; Pierceall WE; Weaver D; Slough S; Wasserman E; Kufe DW; Von Hoff D; Kawabe T; Sharma S
Clin Cancer Res; 2011 May; 17(10):3431-42. PubMed ID: 21220472
[TBL] [Abstract][Full Text] [Related]
5. Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.
Mine N; Yamamoto S; Kufe DW; Von Hoff DD; Kawabe T
Mol Cancer Ther; 2014 Sep; 13(9):2215-25. PubMed ID: 25053821
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract][Full Text] [Related]
7. CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding.
Saito N; Mine N; Kufe DW; Von Hoff DD; Kawabe T
Oncotarget; 2017 Sep; 8(43):74006-74018. PubMed ID: 29088764
[TBL] [Abstract][Full Text] [Related]
8. CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.
Sakakibara K; Sato T; Kufe DW; VonHoff DD; Kawabe T
Oncotarget; 2017 Oct; 8(45):78277-78288. PubMed ID: 29108228
[TBL] [Abstract][Full Text] [Related]
9. Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site.
Matsumoto Y; Shindo Y; Takakusagi Y; Takakusagi K; Tsukuda S; Kusayanagi T; Sato H; Kawabe T; Sugawara F; Sakaguchi K
Bioorg Med Chem; 2011 Dec; 19(23):7049-56. PubMed ID: 22032894
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.
Hsu WH; Zhao X; Zhu J; Kim IK; Rao G; McCutcheon J; Hsu ST; Teicher B; Kallakury B; Dowlati A; Zhang YW; Giaccone G
J Thorac Oncol; 2019 Jun; 14(6):1032-1045. PubMed ID: 30771522
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Lara PN; Mack PC; Synold T; Frankel P; Longmate J; Gumerlock PH; Doroshow JH; Gandara DR
Clin Cancer Res; 2005 Jun; 11(12):4444-50. PubMed ID: 15958629
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
13. Different profiles of the mRNA levels of DNA repair genes in MCF-7 and SH-SY5Y cells after treatment with combination of cisplatin, 50-Hz electromagnetic field and bleomycin.
Sanie-Jahromi F; Saadat M
Biomed Pharmacother; 2017 Oct; 94():564-568. PubMed ID: 28780472
[TBL] [Abstract][Full Text] [Related]
14. CBP501 suppresses macrophage induced cancer stem cell like features and metastases.
Mine N; Yamamoto S; Saito N; Sato T; Sakakibara K; Kufe DW; VonHoff DD; Kawabe T
Oncotarget; 2017 Sep; 8(38):64015-64031. PubMed ID: 28969049
[TBL] [Abstract][Full Text] [Related]
15. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
[TBL] [Abstract][Full Text] [Related]
16. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
17. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Li Y; Ahmed F; Ali S; Philip PA; Kucuk O; Sarkar FH
Cancer Res; 2005 Aug; 65(15):6934-42. PubMed ID: 16061678
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
